Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral oncolysis.

James M Donahue1, John T Mullen, Kenneth K Tanabe

  • 1Massachusetts General Hospital, Harvard Medical School, Cox 626, 100 Blossom Street, Boston, MA 02114-2696, USA.

Surgical Oncology Clinics of North America
|December 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CD49b (ITGA2) collagen receptor excludes CD8<sup>+</sup> T cell infiltration in pancreatic ductal adenocarcinoma.

iScience·2026
Same author

Patient-derived three-dimensional lung tumor models to evaluate response to therapy.

NPJ precision oncology·2026
Same author

Phase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

ASO Visual Abstract: Surgery vs. Radiation for Stage 1A NSCLC in Nonagenarians: 20 Years of Data, Decisions, and Outcomes.

Annals of surgical oncology·2026
Same author

Single-cell transcriptomics reveals the impact of sex and age in the healthy human liver.

JHEP reports : innovation in hepatology·2026
Same author

Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Oncolytic viral therapy engineers viruses to target and destroy cancer cells. Advances in molecular biology enhance viral potency, specificity, and immune response modulation for improved cancer treatment.

Area of Science:

  • Virology
  • Molecular Biology
  • Genetics

Background:

  • The concept of using viruses against cancer (antineoplastic agents) is nearly a century old.
  • Recent scientific advances allow for engineered viruses with increased tumor-targeting ability and effectiveness.
  • Current strategies include combining oncolytic viruses with chemotherapy and radiation to overcome tumor resistance.

Purpose of the Study:

  • To explore advancements in engineering oncolytic viruses for cancer therapy.
  • To investigate methods for enhancing viral antineoplastic effects through genetic modification and immune response modulation.
  • To assess the safety and efficacy of oncolytic viral therapy in clinical settings.

Main Methods:

  • Engineering viruses for enhanced potency and tumor specificity.

Related Experiment Videos

  • Arming viruses with therapeutic transgenes.
  • Modulating the host immune response to favor antitumor immunity.
  • Investigating viral mechanisms to overcome cellular defenses.

    • Main Results:

    • Initial clinical studies indicate oncolytic viral therapy is safe and well-tolerated for metastatic disease.
    • Genetically modified viruses show antineoplastic effects in humans comparable to preclinical models.
    • Enhanced viral strategies aim to reduce tumor cell clone resistance.

    Conclusions:

    • Oncolytic viral therapy represents a promising advancement in cancer treatment.
    • Further understanding of viral-cellular interactions will improve specificity and reduce toxicity.
    • Engineered oncolytic viruses demonstrate significant potential in both preclinical and clinical cancer studies.